HIV and cancer in Germany;HIV und krebs in Deutschland

Deutsches Arzteblatt

Volumn 108, Issue 8, 2011, Pages 117-122

  Hensel, Manfred ^a,c   Goetzenich, Armin ^b   Lutz, Thomas ^c   Stoehr, Albrecht ^d   Moll, Arend ^e   Rockstroh, Jürgen ^f   Hanhoff, Nicola ^b   Jäger, Hans ^b   Mosthaf, Franz ^c  

^a Mannheimer Onkologie Praxis   (Germany)

^b Deutsche Arbeitsgemeinschaft Niedergelassener Arzte in der Versorg HIV Infizierter eV (Dagnae)   (Germany)

^c Infektiologikum Frankfurt/Main ^*  (Germany)

^d DEPARTMENT OF CARDIOLOGY   (Germany)

^e Praxiszentrum Kaiserdamm   (Germany)

^f UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PREDNISONE; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMBULATORY CARE; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANUS CARCINOMA; ARTICLE; B CELL LYMPHOMA; BRAIN LYMPHOMA; BREAST CANCER; BURKITT LYMPHOMA; CANCER SCREENING; CANCER STAGING; COLON CANCER; COLORECTAL CARCINOMA; COMORBIDITY; EPIDEMIC; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOBLASTIC LYMPHOMA; INCIDENCE; KAPOSI SARCOMA; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PROSTATE CANCER; REMISSION; SKIN CANCER; SOLID TUMOR; STRUCTURED QUESTIONNAIRE; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA;

ADULT; AGED, 80 AND OVER; AMBULATORY CARE; COMORBIDITY; FEMALE; GERMANY; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; YOUNG ADULT;

EID: 79952944692     PISSN: 00121207     EISSN: 01722107     Source Type: Journal    
DOI: 10.3238/arztebl.2010.0117     Document Type: Article

References (31)

1. Herida M, Mary-Krause M, Kaphan R, et al.: Incidence of non-Aids-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003; 21: 3447-53. (Pubitemid 46594077)
2. Lewden C, May T, Rosenthal E, et al.: ANRS EN19 Mortalité Study Group and Mortavic1: Changes in causes of death among adults infected by HIV between 2000 and 2005: The .,Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48: 590-8.
3. Bonnet F, Chêne G, Thiébaut R, et al.: Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA): Trends and determinants of severe morbidity in HIV-infected patients: the ANRS CO3 Aquitaine Cohort, 2000-2004. HIV Med 2007; 8: 547-54.
4. Lewden C, Salmon D, Morlat P, et al.: Mortality 2000 study group: Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of Aids. Int J Epidemiol 2005; 34: 121-30.
5. Bonnet F, Burty C, Lewden C, et al.: Agence Nationale de Recherches sur le Sida et les Hépatites Virales EN19 Mortalité Study Group; Mortavic Study Group: Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey. Clin Infect Dis 2009; 48: 633-9.
6. Dal Maso L, Polesel J, Serraino D, et al.: Cancer and Aids Registries Linkage (CARL) Study. Pattern of cancer risk in persons with Aids in Italy in the HAART era. Br J Cancer 2009; 100: 840-7.
7. Spano JP, Costagliola D, Katlama C, Mounier N, Oksenhendler E, Khayat D: Aids-related malignancies: state of the art and therapeutic challenges. J Clin Oncol 2008; 26: 4834-42.
8. Bonnet F, Chêne G: Evolving epidemiology of malignancies in HIV. Curr Opin Oncol 2008; 20: 534-40.
9. Hoffmann C, Wolf E, Wyen C, et al.: Aids-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective. Leuk Lymphoma 2006; 47: 1872-80. (Pubitemid 44649772)
10. Hoffmann C, Chow KU, Wolf E, et al.: Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease. Br J Haematol 2004; 125: 455-62. (Pubitemid 38916190)
11. Hentrich M, Maretta L, Chow KU, et al.: Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. Ann Oncol 2006; 17: 914-9. (Pubitemid 43778980)
12. Hartmann P, Rehwald U, Salzberger B, et al.: BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection. Ann Oncol 2003; 14: 1562-9. (Pubitemid 37304614)
13. Mosthaf FA, Hanhoff NJ, Goetzenich A, Wolf E, Knechten H: Hohe Inzidenz nicht Aids-definierender Neoplasien bei HIV-infizierten Patienten in Deutschland. Ein 3-jähriger bundesweiter Überblick [High incidence of non-Aids-defined cancers among HIV-infected patients in Germany. A 3-year nationwide review]. Dtsch Med Wochenschr 2006; 131: 1849-52.
14. Chow KU, Mitrou PS, Geduldig K, Helm EB, Hoelzer D, Brodt HR: Changing incidence and survival in patients with aids-related non-Hodgkin's lymphomas in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma 2001; 41: 105-16. (Pubitemid 32294194)
15. Wyen C, Fätkenheuer G, Hoffmann C: Die deutsche Lymphomkohorteaktueller Stand. In: Hoffmann, Jäger (eds.): Aids 2008. Berlin, Wiley-Blackwell 2008
16. Engels EA, Biggar RJ, Hall HI, et al.: Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123: 187-94 (Pubitemid 351705208)
17. Rauch A, Gaudieri S, Evison J, et al.: Low current and nadir CD4+ T-cell counts are associated with higher hepatitis C virus RNA levels in the Swiss HIV cohort study. Antivir Ther 2008; 13: 455-60. (Pubitemid 352016738)
18. Crum-Cianflone N, Hullsiek KH, Marconi V, et al.: Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. Aids 2009; 23: 41-50.
19. Silverberg MJ, Neuhaus J, Bower M, et al.: Risk of cancers during interrupted antiretroviral therapy in the SMART study. Aids 2007; 21: 1957-63. (Pubitemid 47329772)
20. Silverberg MJ, Chao C, Leyden WA, et al.: HIV infection and the risk of cancers with and without a known infectious cause. Aids 2009; 23: 2337-45.
21. Clifford GM, Rickenbach M, Lise M, et al.: Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood 2009; 113: 5737-42.
22. Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF: HIV-associated lymphomas and gamma-herpesviruses. Blood 2009; 113: 1213-24.
23. Diamond C, Taylor TH, Aboumrad T, Anton-Culver H: Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. Cancer 2006; 106: 128-35. (Pubitemid 43032557)
24. Berretta M, Cappellani A, Di Benedetto F, et al.: Clinical presentation and outcome of colorectal cancer in HIV-positive patients: a clinical casecontrol study. Onkologie 2009; 32: 319-24.
25. Mosthaf F: HIV-Infektion: Jährliche Tumorvorsorge. Dtsch Arztebl 2004; 101: A 1074
26. Ancelle-Park R: Expanded European Aids case definition. Lancet 1993; 341(8842): 441.
27. Palefsky JM, Minkoff H, Kalish LA, et al.: Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999; 91: 226-36.
28. Knowles DM: Etiology and pathogenesis of Aids-related non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 2003; 17: 785-820.
29. Capello D, Scandurra M, Poretti G, et al.: Genome wide DNA-profiling of HIV-related B-cell lymphomas. Br J Haematol 2010; 148: 245-55.
30. Simonelli C, Tedeschi R, Gloghini A, et al.: Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection. J Med Virol 2009; 81: 888-96.
31. Carbone A, Gloghini A, Serraino D, Spina M: HIV-associated Hodgkin lymphoma. Curr Opin HIV Aids 2009; 4: 3-10.